Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
出版年份 2012 全文链接
标题
Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
作者
关键词
-
出版物
Clinical & Translational Oncology
Volume 14, Issue 10, Pages 726-739
出版商
Springer Nature
发表日期
2012-07-26
DOI
10.1007/s12094-012-0856-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- (2011) C. Mao et al. ANNALS OF ONCOLOGY
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
- (2011) Richard G. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers
- (2011) Katharina Balschun et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle
- (2011) S. Tejpar et al. JNCI-Journal of the National Cancer Institute
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
- (2010) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis
- (2010) Mohamed Bouchahda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Colorectal Cancer OncoGuia: surgical pathology report guidelines
- (2010) Xavier Sanjuán et al. Clinical & Translational Oncology
- Clinical significance of tumor suppressor PTEN in colorectal carcinoma
- (2010) C.P. Hsu et al. EJSO
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin
- (2010) Michael J. O'Connell et al. JOURNAL OF CLINICAL ONCOLOGY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
- (2010) Ramon Salazar et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
- (2010) Zaina Sangale et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer
- (2009) K.-L. G. Spindler et al. ANNALS OF ONCOLOGY
- PTEN status in advanced colorectal cancer treated with cetuximab
- (2009) F V Negri et al. BRITISH JOURNAL OF CANCER
- Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
- (2009) R L Rego et al. BRITISH JOURNAL OF CANCER
- Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma
- (2009) Ki-Seok Jang et al. HISTOPATHOLOGY
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CAMutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
- (2009) Shuji Ogino et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH
- (2009) Chris Hemmings et al. PATHOLOGY
- Current overview of the role of Akt in cancer studies via applied immunohistochemistry
- (2008) Viktor Shtilbans et al. Annals of Diagnostic Pathology
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- EGFR and colon cancer: a clinical view
- (2008) Javier de Castro-Carpeño et al. Clinical & Translational Oncology
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now